ANAVEX LIFE SCIENCES CORP.

AVXL

ANAVEX LIFE SCIENCES CORP.

AVXL

Insider Sentiment (TTM):

Last Purchase:2024-06-14Last Sale:2024-03-28Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:38,566,477Shares Outstanding:89,029,458Institutional Ownership Pct.:43.32%

Earnings Market Reaction:

Filing Date:2026-02-09Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Biological Products, (No Diagnostic Substances)

AMGN GILD SCLX BIIB MRNA RVMD

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	132	103	101	116	121	132	139	139	144	151	155	153
Income Taxes Receivable	1	1	1	1	3	2	2	4	4	3	2	5
Prepaid Expense And Other Assets Current	0	0	0	1	1	1	1	1	1	1	1	1
Assets	133	104	102	117	124	136	142	145	148	154	158	159
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	4	7	7	5	10	4	4	4	4	4	6
Accrued Liabilities Current	3	4	4	10	8	5	7	5	7	7	6	7
Deferred Income Current	-	-	1	1	1	-	1	1	1	-	1	1
Deferred Rent Credit	1	1	-	-	-	1	-	-	-	1	-	-
Liabilities	6	9	11	17	13	15	12	10	12	13	11	14
Preferred Stock Value	-	-	0	-	-	-	-	0	-	-	-	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	515	477	463	459	459	456	454	447	437	435	430	417
Retained Earnings Accumulated Deficit	-388	-382	-373	-359	-348	-336	-324	-312	-302	-293	-283	-272
Stockholders Equity	127	95	91	100	111	120	130	135	136	142	147	145
Liabilities And Stockholders Equity	133	104	102	117	124	136	142	145	148	154	158	159
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Issued	278	260	256	256	255	254	254	251	246	246	244	241
Shares Outstanding	93	87	85	85	85	85	85	84	82	82	81	80

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	6.90%	-31.26%	-23.68%	-	-	-	-	-	-	-	-	-
2025	-0.34%	-5.86%	7.59%	1.85%	32.88%	37.93%	-12.80%	-7.61%	-26.07%	6.07%	44.80%	13.58%
2024	-5.55%	-8.94%	-38.46%	4.64%	8.76%	73.71%	-11.67%	-16.65%	-23.11%	-17.62%	-23.79%	-15.65%
2023	-	-	-	0.77%	-10.36%	-12.57%	-1.12%	-18.43%	-35.24%	40.72%	-4.87%	-10.85%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Leverage & Debt
Interest Coverage TTM	-10.22	-10.99	-10.08	-8.93	-8.22	-7.22	-6.82	-6.65	-7.13	-8.55	-11.09	-15.63
Per Share Metrics
Diluted EPS TTM	-0.45	-0.54	-0.56	-0.55	-0.55	-0.52	-0.49	-0.49	-0.53	-0.60	-0.64	-0.67
Free Cash Flow Per Share TTM	-0.38	-0.46	-0.43	-0.35	-0.42	-0.37	-0.35	-0.39	-0.36	-0.35	-0.32	-0.32
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-14.08%	7.85%	15.99%	16.13%	7.73%	-9.48%	-19.60%	-23.03%	-13.81%	-0.99%	13.75%	22.02%
EPS Growth (1Y)	-18.15%	5.55%	14.85%	12.57%	4.26%	-13.47%	-23.08%	-26.91%	-18.11%	-4.56%	228.88%	260.73%
Valuation Metrics
P/E TTM	-7.93	-16.37	-16.34	-15.48	-19.59	-11.03	-8.59	-10.34	-17.71	-11.00	-12.73	-12.72
P/B TTM	2.50	8.00	8.65	7.32	8.21	3.94	2.75	3.11	5.64	3.68	4.48	4.62
Market Cap	316.94M	759.08M	787.21M	729.93M	910.82M	474.10M	356.74M	419.74M	764.14M	522.61M	657.52M	671.07M
Enterprise Value	185.20M	656.50M	686.05M	614.16M	790.04M	341.91M	217.98M	280.36M	620.38M	371.58M	502.70M	517.60M
Calculated Values
Free Cash Flow TTM	-34.08M	-39.04M	-37.10M	-29.81M	-35.61M	-30.81M	-30.00M	-32.48M	-29.31M	-27.79M	-25.98M	-25.38M
Net Debt	-131.75M	-102.58M	-101.16M	-115.77M	-120.78M	-132.19M	-138.76M	-139.39M	-143.77M	-151.02M	-154.82M	-153.47M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-06-14Purchase

Owner: Donhauser, Peter D.O.

Title: -

Shares: 2,835

Price/Share: $3.64

Value: $10,319.40

Shares Owned: 5,000

Relationship: Director

Ownership: Direct

2024-05-15Purchase

Owner: Thomas, Steffen

Title: -

Shares: 5,000

Price/Share: $4.52

Value: $22,600.00

Shares Owned: 5,000

Relationship: Director

Ownership: Direct

2024-03-28Sale

Owner: Missling, Christopher U

Title: President and CEO

Shares: 73,380

Price/Share: $5.11

Value: $374,971.80

Shares Owned: 1,250,210

Relationship: Director,Officer

Ownership: Direct

2023-06-28Sale

Owner: Missling, Christopher U

Title: President and CEO

Shares: 268,000

Price/Share: $7.98

Value: $2,138,640.00

Shares Owned: 1,018,210

Relationship: Director,Officer

Ownership: Direct

2022-05-25Sale

Owner: Skarpelos, Athanasios

Title: -

Shares: 50,000

Price/Share: $9.06

Value: $453,000.00

Shares Owned: 1,306,458

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-06-14	Donhauser, Peter D.O.	Director	-	Direct	Purchase	2,835	3.64	$10,319.40	5,000	4
2024-05-15	Thomas, Steffen	Director	-	Direct	Purchase	5,000	4.52	$22,600.00	5,000	4
2024-03-28	Missling, Christopher U	Director,Officer	President and CEO	Direct	Sale	73,380	5.11	$374,971.80	1,250,210	4
2023-06-28	Missling, Christopher U	Director,Officer	President and CEO	Direct	Sale	268,000	7.98	$2,138,640.00	1,018,210	4
2022-05-25	Skarpelos, Athanasios	Director	-	Direct	Sale	50,000	9.06	$453,000.00	1,306,458	4
2021-06-29	Missling, Christopher U	Director,Officer	President and CEO	Direct	Sale	51,620	26.00	$1,342,120.00	1,018,210	4
2021-06-29	Boenisch, Sandra	Officer	PFO and Treasurer	Direct	Sale	166,696	26.53	$4,422,444.88	22,963	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

43.32%

Inst. Shares: 38,566,477

Shares Outstanding: 89,029,458

2025-12-31

42.83%

Inst. Shares: 38,131,677

Shares Outstanding: 89,029,458

2025-09-30

37.36%

Inst. Shares: 31,862,842

Shares Outstanding: 85,289,447

2025-06-30

37.17%

Inst. Shares: 31,737,122

Shares Outstanding: 85,380,587

2025-03-31

35.81%

Inst. Shares: 30,468,615

Shares Outstanding: 85,073,769

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	38,566,477	89,029,458	43.32%
2025-12-31	38,131,677	89,029,458	42.83%
2025-09-30	31,862,842	85,289,447	37.36%
2025-06-30	31,737,122	85,380,587	37.17%
2025-03-31	30,468,615	85,073,769	35.81%
2024-12-31	28,812,007	84,805,974	33.97%
2024-09-30	27,017,221	83,468,049	32.37%
2024-06-30	25,991,533	84,535,328	30.75%
2024-03-31	31,212,427	82,464,226	37.85%
2023-12-31	24,874,502	82,077,815	30.31%
2023-09-30	24,217,010	79,787,596	30.35%
2023-06-30	24,448,083	80,875,235	30.23%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

ANAVEX LIFE SCIENCES CORP. (AVXL) — SEC Financial Statements & Analysis

ANAVEX LIFE SCIENCES CORP. (AVXL) is a biological products, (no diagnostic substances) company. ANAVEX LIFE SCIENCES CORP. trades on AVXL: Nasdaq as: AVXL. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), ANAVEX LIFE SCIENCES CORP. reported a Price-to-Book (P/B) ratio of 2.5 (TTM), at a market cap of $316.94M. Figures below are sourced from SEC EDGAR, as-filed.

P/B TTM: 2.5
Market Cap: $316.94M

Data as of 2025-12-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ANAVEX LIFE SCIENCES CORP. in?

ANAVEX LIFE SCIENCES CORP. (AVXL) operates in the Biological Products, (No Diagnostic Substances) industry.

What is AVXL's market cap?

ANAVEX LIFE SCIENCES CORP. (AVXL) has a market capitalization of $316.94M as of 2025-12-31.

What exchange does AVXL trade on?

ANAVEX LIFE SCIENCES CORP. (AVXL) trades on the AVXL: Nasdaq.

ANAVEX LIFE SCIENCES CORP. (AVXL) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.